Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion, Orbitrap Exploris 480, Q Exactive HF, Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): B Cell, Cell Culture
DISEASE(S): Diffuse Large B-cell Lymphoma
SUBMITTER: Sebastian Scheich
LAB HEAD: Louis M. Staudt
PROVIDER: PXD041092 | Pride | 2025-05-06
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
File_assignment.txt | Txt | |||
MQ_005.zip | Other | |||
MQ_011.zip | Other | |||
MQ_34-42.zip | Other | |||
MQ_441.zip | Other |
Items per page: 5 1 - 5 of 1164 |
Phelan James D JD Scheich Sebastian S Choi Jaewoo J Wright George W GW Häupl Björn B Young Ryan M RM Rieke Sara A SA Pape Martine M Ji Yanlong Y Urlaub Henning H Bolomsky Arnold A Doebele Carmen C Zindel Alena A Wotapek Tanja T Kasbekar Monica M Collinge Brett B Huang Da Wei DW Coulibaly Zana A ZA Morris Vivian M VM Zhuang Xiaoxuan X Enssle Julius C JC Yu Xin X Xu Weihong W Yang Yandan Y Zhao Hong H Wang Zhuo Z Tran Andy D AD Shoemaker Christopher J CJ Shevchenko Galina G Hodson Daniel J DJ Shaffer Arthur L AL Staudt Louis M LM Oellerich Thomas T
Cancer cell 20240111 2
Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on chronic active BCR signaling to promote oncogenic NF-κB. The MCD genetic subtype, which often acquires mutations in the BCR subunit, CD79B, and in the innate immune adapter, MYD88<sup>L265P</sup>, typi ...[more]